68Ga-FAP-RGD PET/CT : Dosimetry and Preliminary Clinical Translational Studies

Launched by FIRST AFFILIATED HOSPITAL OF FUJIAN MEDICAL UNIVERSITY · Aug 23, 2022

Keywords

ClinConnect Summary

This clinical trial is testing a new imaging tool called 68Ga-FAP-RGD, which helps doctors see and understand different types of tumors in the body. The study aims to find out how safe this tool is, how it is distributed in the body, and how it compares to other imaging methods already in use, like 68Ga-FAPI-02 or 18F-FDG. By using this new imaging agent, researchers hope to improve the way cancers are diagnosed and treated.

To participate in this study, you need to have a solid tumor and be between the ages of 65 and 74. You will also need to sign a consent form to show that you understand and agree to participate. Unfortunately, pregnant or nursing women and those with serious liver or kidney problems cannot join. If you decide to participate, you can expect to undergo imaging procedures that help researchers gather important information about your cancer while ensuring your safety throughout the process.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Various solid tumors with available histopathological findings
• • Signed informed consent
• Exclusion Criteria:
• • pregnant or lactational women
• • who suffered from severe hepatic and renal insufficiency